Demand for International Pharma Manufacturers and Ingredients Increasing in Russia
News Feb 24, 2016
CPhI Russia @ IPhEB, organised by UBM EMEA, returns for the fourth consecutive year in Russia as business opportunities in the country remain diverse, with companies looking to gain access to the Commonwealth of Independent States (CIS) and Central East European (CEE) regions.
The event is taking place at JSC VDNH (VVC), Moscow, 30th March-1st April 2016 and includes IPhEB Conference (forum), which provides key insights into the local market. One of the key sessions in this forum is a master class on strategy and procedure for companies and products ahead of market launch in the region. Market Access tactics and implementation will be developed at the master class, including how to evaluate the medical importance of a disease, therapeutic and pharma economic viability, its prevalence over the existing treatment methods, and availability.
Russia’s pharmaceutical market is positioned at the forefront of the pharma emerging markets, with the Government’s ambitious Pharma 2020 plan continuing apace, demand for international pharmaceutical ingredients, manufacturing and packaging equipment is increasing in order to upgrade existing manufacturing sites to GMP standards. Russia’s 2020 plan, introduced in 2009, provides direct investment by the Government, with nearly US$5billion in funding, and the goal of increasing domestic finished-dose pharmaceutical manufacturing and R&D capabilities.
The country has attracted a strong base of international pharma companies – an overwhelming 76% of total pharmaceutical sales are attributed to imported drugs – with many more foreign manufacturers now looking to capitalise on this attractive market. Integral to the internationalization of this market is CPhI Russia, which acts a central hub for buyers and sellers within the region, providing a vital platform where pharma executives can connect, build and nurture existing relationships.
Growth in the domestic market has enabled CPhI Russia @ IPhEB to expand year-on-year, and in 2016, the three-in-one event will welcome more than 3000 attendees – in 2015, 231 exhibitors attended from 67 different countries. Exhibitors include some of the largest companies in pharmaceutical ingredients, machinery, equipment and technology (P-MEC), packaging and drug delivery systems (InnoPack), alongside domestic heavyweights Pharmasyntez, Indukern, Protek-SVM, Merck, Serdix, Kelun Kazfarm, and Sotex.
Robert Rosen, Director General of Selecta (RUS) Company, Bind (RUS), comments: "Last year was a very interesting event that facilitates the future development of science and pharmaceuticals. It helped our company to understand and find potential niches, research and administrative resources, and also business partners. CPhI Russia @ IPhEB provides all the opportunities for future, successful work. We are delighted to be returning to Moscow and actively contributing to new industry developments and Russia’s pharma expansion".
This year the highlights of the event include:
• IPhEB Conference running throughout the event, providing key insights into the local market, including sessions on: ‘pilot projects aimed at pharmacological support’; ‘present-day requirements for accreditation pharmaceutical industry professionals’; ‘food supplements verses Medicines’; and a master class in ‘market access in healthcare’.
• Speakers Corner, presenting a quick ‘snapshot’ of the different exhibitor offerings, trends and innovations on the exhibition floor.
• Matchmaking program, which is complimentary to use for all attendees. It helps visitors and exhibitors find the companies that best match their business needs. Enabling them to pre-plan their schedule and provides a dedicated area solely designated to hosting meetings.
Erick Heemsterk, Brand Director Pharma at UBM EMEA, commenting on the impact CPhI Russia @ IPhEB is having on the region: “2016 is the second year we have been based in Moscow and it enables us to be close to the Russian policy makers; the 2020 plan is one of the most important drivers for the Russian pharmaceutical industry. Russia is a complex market, but one ripe with future potential, and the content and market analysis at the event helps both domestic and international companies evaluate the opportunities. Whilst the CPhI exhibition facilitates the essential meetings in helping this market reach its full potential.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
15th Symposium on the Practical Applications of Mass Spectrometry in the Biotechnology Industry
Sep 09 - Sep 12, 2018
CE in the Biotechnology & Pharmaceutical Industries: 20th Symposium on the Practical Applications for the Analysis of Proteins, Nucleotides & Small Molecules
Sep 09 - Sep 12, 2018